Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

CD71 improves delineation of PNH type III, PNH type II, and normal immature RBCS in patients with paroxysmal nocturnal hemoglobinuria

DR. Sutherland, SJ. Richards, F. Ortiz, R. Nayyar, M. Benko, I. Marinov, A. Illingworth

. 2020 ; 98 (2) : 179-192. [pub] 20191108

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21020705

BACKGROUND: The diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) relies on flow cytometric demonstration of loss of glycosyl-phosphatidyl inositol (GPI)-anchored proteins from red blood cells (RBC) and white blood cells (WBC). High-sensitivity multiparameter assays have been developed to detect loss of GPI-linked structures on PNH neutrophils and monocytes. High-sensitivity assays to detect PNH phenotypes in RBCs have also been developed that rely on the loss of GPI-linked CD59 on CD235a-gated mature RBCs. The latter is used to delineate PNH Type III (total loss of CD59) and PNH Type II RBCs (partial loss of CD59) from normal (Type I) RBCs. However, it is often very difficult to delineate these subsets, especially in patients with large PNH clones who continue to receive RBC transfusions, even while on eculizumab therapy. METHODS: We have added allophycocyanin (APC)-conjugated CD71 to the existing CD235aFITC/CD59PE RBC assay allowing simultaneous delineation and quantification of PNH Type III and Type II immature RBCs (iRBCs). RESULTS: We analyzed 24 medium to large-clone PNH samples (>10% PNH WBC clone size) for PNH Neutrophil, PNH Monocyte, Type III and Type II PNH iRBCs, and where possible, Type III and Type II PNH RBCs. The ability to delineate PNH Type III, Type II, and Type I iRBCs was more objective compared to that in mature RBCs. Additionally, total PNH iRBC clone sizes were very similar to PNH WBC clone sizes. CONCLUSIONS: Addition of CD71 significantly improves the ability to analyze PNH clone sizes in the RBC lineage, regardless of patient hemolytic and/or transfusion status.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020705
003      
CZ-PrNML
005      
20250611091542.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cyto.b.21853 $2 doi
035    __
$a (PubMed)31705743
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sutherland, D Robert $u Laboratory Medicine Program, Toronto General Hospital, Toronto, Ontario, Canada
245    10
$a CD71 improves delineation of PNH type III, PNH type II, and normal immature RBCS in patients with paroxysmal nocturnal hemoglobinuria / $c DR. Sutherland, SJ. Richards, F. Ortiz, R. Nayyar, M. Benko, I. Marinov, A. Illingworth
520    9_
$a BACKGROUND: The diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) relies on flow cytometric demonstration of loss of glycosyl-phosphatidyl inositol (GPI)-anchored proteins from red blood cells (RBC) and white blood cells (WBC). High-sensitivity multiparameter assays have been developed to detect loss of GPI-linked structures on PNH neutrophils and monocytes. High-sensitivity assays to detect PNH phenotypes in RBCs have also been developed that rely on the loss of GPI-linked CD59 on CD235a-gated mature RBCs. The latter is used to delineate PNH Type III (total loss of CD59) and PNH Type II RBCs (partial loss of CD59) from normal (Type I) RBCs. However, it is often very difficult to delineate these subsets, especially in patients with large PNH clones who continue to receive RBC transfusions, even while on eculizumab therapy. METHODS: We have added allophycocyanin (APC)-conjugated CD71 to the existing CD235aFITC/CD59PE RBC assay allowing simultaneous delineation and quantification of PNH Type III and Type II immature RBCs (iRBCs). RESULTS: We analyzed 24 medium to large-clone PNH samples (>10% PNH WBC clone size) for PNH Neutrophil, PNH Monocyte, Type III and Type II PNH iRBCs, and where possible, Type III and Type II PNH RBCs. The ability to delineate PNH Type III, Type II, and Type I iRBCs was more objective compared to that in mature RBCs. Additionally, total PNH iRBC clone sizes were very similar to PNH WBC clone sizes. CONCLUSIONS: Addition of CD71 significantly improves the ability to analyze PNH clone sizes in the RBC lineage, regardless of patient hemolytic and/or transfusion status.
650    _2
$a CD antigeny $x krev $x fyziologie $7 D015703
650    _2
$a antigeny CD59 $x metabolismus $7 D018957
650    _2
$a buněčná diferenciace $7 D002454
650    _2
$a kohortové studie $7 D015331
650    _2
$a diferenciální diagnóza $7 D003937
650    _2
$a erytrocyty $x metabolismus $x patologie $7 D004912
650    _2
$a průtoková cytometrie $x přístrojové vybavení $x metody $x normy $7 D005434
650    _2
$a glykoforin $x metabolismus $7 D006021
650    _2
$a paroxysmální hemoglobinurie $x krev $x klasifikace $x diagnóza $x patologie $7 D006457
650    _2
$a lidé $7 D006801
650    _2
$a imunofenotypizace $x přístrojové vybavení $x metody $x normy $7 D016130
650    _2
$a počet leukocytů $x přístrojové vybavení $x metody $7 D007958
650    _2
$a leukocyty $x patologie $7 D007962
650    _2
$a monocyty $x metabolismus $x patologie $7 D009000
650    _2
$a neutrofily $x metabolismus $x patologie $7 D009504
650    _2
$a receptory transferinu $x krev $x fyziologie $7 D011990
655    _2
$a časopisecké články $7 D016428
700    1_
$a Richards, Stephen J $u HMDS, St James University Hospital, Leeds, UK & Experimental Haematology, University of Leeds, UK
700    1_
$a Ortiz, Fernando $u Sprott Centre for Stem Cell Research, Ottawa Hospital Research Institute, Toronto, Ontario, Canada
700    1_
$a Nayyar, Rakesh $u Cytoquest Corporation, Toronto, Ontario, Canada
700    1_
$a Benko, M. $u EXBIO, Praha, a.s. Vestec, Czech Republic $7 xx0332972
700    1_
$a Marinov, Iuri $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Illingworth, Andrea $u Dahl-Chase Diagnostic Services, Bangor, Maine
773    0_
$w MED00013936 $t Cytometry. Part B, Clinical cytometry $x 1552-4957 $g Roč. 98, č. 2 (2020), s. 179-192
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31705743 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20250611091534 $b ABA008
999    __
$a ok $b bmc $g 1691310 $s 1141151
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 98 $c 2 $d 179-192 $e 20191108 $i 1552-4957 $m Cytometry. Part B, Clinical cytometry $n Cytometry B Clin Cytom $x MED00013936
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options